Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MELPHALAN for B-cell type acute leukaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where MELPHALAN was used for B-cell type acute leukaemia.

Most Reported Side Effects for MELPHALAN

Side Effect Reports % Deaths Hosp.
Off label use 2,002 12.5% 437 495
Febrile neutropenia 931 5.8% 145 419
Drug ineffective 853 5.3% 199 213
Neutropenia 810 5.0% 145 246
Mucosal inflammation 804 5.0% 131 254
Plasma cell myeloma 781 4.9% 223 99
Product use in unapproved indication 765 4.8% 144 182
Thrombocytopenia 701 4.4% 118 253
Diarrhoea 698 4.4% 95 343
Pyrexia 667 4.2% 144 346
Pneumonia 650 4.1% 254 382
Disease progression 595 3.7% 155 90
Myelodysplastic syndrome 573 3.6% 231 132
Sepsis 544 3.4% 316 247
Venoocclusive liver disease 464 2.9% 152 130

Other Indications for MELPHALAN

Plasma cell myeloma (4,878) Bone marrow conditioning regimen (2,368) Product used for unknown indication (963) Stem cell transplant (738) Retinoblastoma (715) Diffuse large b-cell lymphoma (595) Neuroblastoma (495) Allogenic stem cell transplantation (374) Hodgkin's disease (351) Autologous haematopoietic stem cell transplant (284)

Other Drugs Used for B-cell type acute leukaemia

METHOTREXATE (925) VINCRISTINE (889) BLINATUMOMAB (622) DEXAMETHASONE (606) CYCLOPHOSPHAMIDE (586) CYTARABINE (582) PEGASPARGASE (374) DOXORUBICIN (360) TISAGENLECLEUCEL (354) MERCAPTOPURINE (308)

Related Pages

MELPHALAN Full Profile All B-cell type acute leukaemia Drugs MELPHALAN Demographics MELPHALAN Timeline